dose titration study terazosin selective once-a-day alpha treatment symptomatic benign prostatic hyperplasia efficacy safety terazosin selective long-acting blocker normotensive patients symptomatic benign prostatic hyperplasia years old patients complete urodynamic evaluation transrectal prostatic ultrasonography enrollment study dose terazosin day interval provided adverse drug reactions patients dose titration study parameters effectiveness terazosin peak mean urinary flow rates micturition symptom scores global assessment patient symptomatic improvement Over-all mean systolic diastolic blood pressures peak mean urinary flow rates obstructive irritative symptom scores Over-all participants voiding symptoms terazosin patients dose titration study due development adverse drug reactions erectile dysfunction tiredness light-headedness palpitations nasal congestion asymptomatic hypotension patients terazosin months mean months improvements urinary flow rates symptom scores interval preliminary experience terazosin encouraging ultimate role terazosin long-term treatment benign prostatic hyperplasia evaluation 